No products in the cart.
Rabbit Polyclonal Phospho-IKKgamma (S85) antibody (STJ90543)
Supplier: St John’s Laboratory Ltd.
Recommended applications: WB, IHC, ELISA
Recommended dilution: WB 1:500-1:2000; IHC 1:100-1:300; ELISA 1:40000;
Recommended protocols: check protocols
Click or hover above images to see image description for IKKgamma (phospho Ser85) Polyclonal Antibody.
Check alternative names for the antibodyExpand
IKBKG antibody, FIP3 antibody, NEMO antibody,|IkB kinase associated protein 1 antibody| IkB kinase subunit gamma antibody| Inhibitor of nuclear factor kappa B kinase subunit gamma antibody|AMCBX1 antibody|FIP 3 antibody|FIP-3 antibody|FIP3 antibody|Fip3p antibody|I kappa B kinase gamma antibody|I-kappa-B kinase subunit gamma antibody|IkB kinase gamma subunit antibody|IkB kinase subunit gamma antibody|IkB kinase-associated protein 1 antibody|Ikbkg antibody|IKK-gamma antibody|IKKAP1 antibody|IKKG antibody|IMD33 antibody|Incontinentia pigmenti antibody|Inhibitor of kappa light polypeptide gene enhancer in B cells, kinase gamma antibody|Inhibitor of kappa light polypeptide gene enhancer in B cells, kinase of, gamma antibody|Inhibitor of nuclear factor kappa-B kinase subunit gamma antibody|IP antibody|IP1 antibody|IP2 antibody|IPD2 antibody|NEMO antibody|NEMO_HUMAN antibody|NF kappa B essential modifier antibody|NF kappa B essential modulator antibody|NF-kappa-B essential modifier antibody|NF-kappa-B essential modulator antibody|ZC2HC9 antibody|Anti-IKK gamma antibody [EPR16629] (ab178872)
SCBT cat No: sc-71331|sc-52930|sc-56919|sc-166700|sc-8032|sc-166398|sc-166397|sc-8330|sc-8256|sc-101430|sc-52931|
IKKgamma (phospho Ser85) Polyclonal Antibody
|Catalogue No.|| |
Phospho-IKKgamma (S85) Polyclonal Antibody detects endogenous levels of IKKgamma protein only when phosphorylated at S85.
Synthesized phospho-peptide derived from IKKgamma (phospho Ser85) at AA range 30-110
WB, IHC, ELISA
|Recommended dilution|| |
WB 1:500-1:2000; IHC 1:100-1:300; ELISA 1:40000;
|Molecular weight|| |
IKKgamma (phospho Ser85) Antibody was tube-contained. Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
IKKgamma (phospho Ser85) Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
-20 Celsius degree. Avoid repeated freeze/thaw cycles.
|Alternative antibody names|| |
NF-kappa-B essential modulator antibody, NEMO antibody, FIP-3 antibody, IkB kinase-associated protein 1 antibody, IKKAP1 antibody, Inhibitor of nuclear factor kappa-B kinase subunit gamma antibody, I-kappa-B kinase subunit gamma antibody, IKK-gamma antibody, IKKG antibody, IkB kinase subunit gamma antibody, NF-kappa-B essential modifier antibody
|Protein names|| |
NF-kappa-B essential modulator , NEMO , FIP-3 , IkB kinase-associated protein 1 , IKKAP1 , Inhibitor of nuclear factor kappa-B kinase subunit gamma , I-kappa-B kinase subunit gamma , IKK-gamma , IKKG , IkB kinase subunit gamma , NF-kappa-B essential modifier
|Protein function|| |
Regulatory subunit of the IKK core complex which phosphorylates inhibitors of NF-kappa-B thus leading to the dissociation of the inhibitor/NF-kappa-B complex and ultimately the degradation of the inhibitor. Its binding to scaffolding polyubiquitin seems to play a role in IKK activation by multiple signaling receptor pathways. However, the specific type of polyubiquitin recognized upon cell stimulation (either ‘Lys-63’-linked or linear polyubiquitin) and its functional importance is reported conflictingly. Also considered to be a mediator for TAX activation of NF-kappa-B. Could be implicated in NF-kappa-B-mediated protection from cytokine toxicity. Essential for viral activation of IRF3. Involved in TLR3- and IFIH1-mediated antiviral innate response; this function requires ‘Lys-27’-linked polyubiquitination.
|Protein tissue specificity|| |
Heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas.
|Involvement in disease|| |
Ectodermal dysplasia, anhidrotic, with immunodeficiency X-linked (EDAID) [MIM:300291]: A form of ectoderma dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. Characterized by absence of sweat glands, sparse scalp hair, rare conical teeth and immunological abnormalities resulting in severe infectious diseases. . Note: The disease is caused by mutations affecting the gene represented in this entry.; Ectodermal dysplasia, anhidrotic, with immunodeficiency, osteopetrosis and lymphedema (OLEDAID) [MIM:300301]: A form of ectoderma dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. Characterized by the association of anhidrotic ectodermal dysplasia with severe immunodeficiency, osteopetrosis and lymphedema. . Note: The disease is caused by mutations affecting the gene represented in this entry.; Immunodeficiency, NEMO-related, without anhidrotic ectodermal dysplasia (NEMOID) [MIM:300584]: Patients manifest immunodeficiency not associated with other abnormalities, and resulting in increased susceptibility to infections. Patients suffer from multiple episodes of infectious diseases. . Note: The disease is caused by mutations affecting the gene represented in this entry.; Immunodeficiency 33 (IMD33) [MIM:300636]: A X-linked recessive form of Mendelian susceptibility to mycobacterial disease, a rare condition characterized by predisposition to illness caused by moderately virulent mycobacterial species, such as Bacillus Calmette-Guerin (BCG) vaccine, environmental non-tuberculous mycobacteria, and by the more virulent Mycobacterium tuberculosis. Other microorganisms rarely cause severe clinical disease in individuals with susceptibility to mycobacterial infections, with the exception of Salmonella which infects less than 50% of these individuals. . Note: Disease susceptibility is associated with variations affecting the gene represented in this entry.; Recurrent isolated invasive pneumococcal disease 2 (IPD2) [MIM:300640]: Recurrent invasive pneumococcal disease (IPD) is defined as two episodes of IPD occurring at least 1 month apart, whether caused by the same or different serotypes or strains. Recurrent IPD occurs in at least 2% of patients in most series, making IPD the most important known risk factor for subsequent IPD. . Note: The disease is caused by mutations affecting the gene represented in this entry.; Incontinentia pigmenti (IP) [MIM:308300]: A genodermatosis usually prenatally lethal in males. In affected females, it causes abnormalities of the skin, hair, eyes, nails, teeth, skeleton, heart, and central nervous system. The prominent skin signs occur in four classic cutaneous stages: perinatal inflammatory vesicles, verrucous patches, a distinctive pattern of hyperpigmentation and dermal scarring. . Note: The disease is caused by mutations affecting the gene represented in this entry.
|Protein sequence and domain|| |
The leucine-zipper domain and the C2HC-type zinc-finger are essential for polyubiquitin binding and for the activation of IRF3. / Contains 1 C2HC-type zinc finger.
|Protein post-translational modifications|| |
Phosphorylation at Ser-68 attenuates aminoterminal homodimerization. / Polyubiquitinated on Lys-285 through ‘Lys-63’; the ubiquitination is mediated by NOD2 and RIPK2 and probably plays a role in signaling by facilitating interactions with ubiquitin domain-containing proteins and activates the NF-kappa-B pathway. Polyubiquitinated on Lys-399 through ‘Lys-63’; the ubiquitination is mediated by BCL10, MALT1 and TRAF6 and probably plays a role in signaling by facilitating interactions with ubiquitin domain-containing proteins and activates the NF-kappa-B pathway. Monoubiquitinated on Lys-277 and Lys-309; promotes nuclear export. Polyubiquitinated through ‘Lys-27’ by TRIM23; involved in antiviral innate and inflammatory responses. Linear polyubiquitinated on Lys-111, Lys-143, Lys-226, Lys-246, Lys-264, Lys-277, Lys-285, Lys-292, Lys-302, Lys-309 and Lys-326; the head-to-tail polyubiquitination is mediated by the LUBAC complex and plays a key role in NF-kappa-B activation. Polyubiquitinated on Lys-309 and Lys-321 via ‘Lys-27’-linked ubiquitin by Shigella flexneri E3 ubiquitin-protein ligase ipah9.8, leading to its degradation by the proteasome. / Sumoylated on Lys-277 and Lys-309 with SUMO1; the modification results in phosphorylation of Ser-85 by ATM leading to a replacement of the sumoylation by mono-ubiquitination on these residues. / Neddylated by TRIM40, resulting in stabilization of NFKBIA and down-regulation of NF-kappa-B activity.
|Protein cellular localization|| |
Cytoplasm / Nucleus
AntibodyPlus can customize IKKgamma (phospho Ser85) Antibody according to your requirement, including bulk product size,etc. Please contact firstname.lastname@example.org. AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.
St John’s Laboratory Ltd.
|Product type|| |
There are no reviews for this product yet.
By submitting a review, get following benefits:
1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!
There is no extra validation for this product yet.
Check other extra validated antibodies below: